CLIA '88 SIMPLIFICATION PROPOSED BY FIRST LADY
This article was originally published in The Gray Sheet
Executive Summary
CLIA '88 SIMPLIFICATION PROPOSED BY FIRST LADY Hillary Rodham Clinton at the American Medical Association House of Delegates' meeting in Chicago on June 13. "We have to simplify and eliminate the burden from regulation created" by the Clinical Laboratory Improvement Amendments of 1988, Clinton proclaimed. She called CLIA '88 "a well-intentioned law with many unexpected consequences ...that have affected not only those of you in private practice, but public health departments -- like ours in Arkansas - - around the country." CLIA is "one specific issue I want to mention, because I feel strongly about it," Clinton remarked. She called on physicians to "help us know what should be eliminated so that we then can focus in on a very small part of this whole situation -- and eliminate the rest of the regulations that were thrown in on top." The 1988 amendments to CLIA require the roughly 200,000 U.S. clinical labs to meet minimum personnel, quality control and assurance, patient test management and other standards. Implementing regulations, which have met with resistance from professional and trade organizations, could lead to the curtailment or closure of 4,000 physician office labs, according to an April 1992 study cosponsored by AMA and other health groups ("The Gray Sheet" April 27, 1992, p. 6). On June 15, the AMA House of Delegates voted to seek a repeal of the law. The amendment approved by the delegates states that AMA will "establish as primary policy the repeal of the CLIA '88." The motion was passed despite recommendations by the Board of Trustees to oppose only the most onerous portions of the law. The June 15 vote followed heated committee exchanges as to whether that stance would be politically counterproductive. "Repealing anything is difficult," maintained board member Jerald Schenken, MD, who warned members about "congressional zealots" and "horror stories" that might result in public relations problems. "Once we actively seek repeal, our ability to deal with regulators ...will be foreclosed. It's just a practical reality." However, the majority of the house ultimately disagreed. California delegate Gary Krieger, MD, urged the AMA to nullify "this gargantuan inappropriate piece of legislation which is destroying our ability to practice medicine." At its December 1992 interim meeting, the association voted not to seek repeal of the CLIA '88 unless efforts at revising the law failed ("The Gray Sheet" Dec. 14, 1992, p. 35). Rep. John Dingell (D-Mich.), chairman of the House Energy and Commerce Committee, is expected to meet with staffers the week of June 14 to discuss the status of CLIA '88. Topics to be addressed are likely to include potential legislative or regulatory modifications to CLIA. Dingell has been critical of HHS' efforts to implement the law over the past several years ("The Gray Sheet" May 18, 1992, p. 3).
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.